{
    "body": "What is the generic name of Gliolan?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24468659", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22849976", 
        "http://www.ncbi.nlm.nih.gov/pubmed/18389144", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25248327", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23870657"
    ], 
    "ideal_answer": [
        "5-aminolevulinic acid (or 5-ALA) is the generic name of Gliolan. It is approved for fluorescence-guided resections of adult malignant gliomas."
    ], 
    "exact_answer": [
        "5-aminolevulinic acid"
    ], 
    "type": "factoid", 
    "id": "54d73e223706e89528000010", 
    "snippets": [
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 152, 
            "text": "BACKGROUND: Five-aminolevulinic acid (Gliolan, medac, Wedel, Germany, 5-ALA) is approved for fluorescence-guided resections of adult malignant gliomas. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25248327", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 202, 
            "text": "OBJECTIVE: This study evaluates the cost-effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan\u00ae) in patients undergoing surgery for malignant glioma, in standard clinical practice conditions in Spain. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24468659", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 256, 
            "text": "OBJECTIVE: To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan(\u00ae)) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23870657", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 355, 
            "offsetInEndSection": 585, 
            "text": "Today, ALA is approved as Levulan for actinic keratoses, the ALA-methyl ester Metvix for actinic keratoses and basal cell carcinoma, the ALA-hexyl ester Hexvix for the diagnosis of bladder cancer and Gliolan for malignant glioma. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389144", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 655, 
            "offsetInEndSection": 850, 
            "text": "MATERIAL AND METHODS: All patients who had undergone 5-ALA fluorescence-guided surgery due to suspected malignant glioma were included. Patients received a standard preoperative dose of Gliolan. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22849976", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 355, 
            "offsetInEndSection": 583, 
            "text": "Today, ALA is approved as Levulan for actinic keratoses, the ALA-methyl ester Metvix for actinic keratoses and basal cell carcinoma, the ALA-hexyl ester Hexvix for the diagnosis of bladder cancer and Gliolan for malignant glioma", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389144", 
            "endSection": "abstract"
        }
    ]
}